Monitor Atera adoption and consumables revenue trajectory in coming quarters, as the raised guidance implies accelerating growth. The EPS basis mismatch (GAAP vs adjusted) needs clarification; if Street consensus is on an adjusted basis, the actual adjusted EPS was not disclosed, leaving uncertainty.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 6 $59.28entry
- T+1 · 8d ago +9.73%α +7.37% · $65.05
- T+5 · 4d ago −1.84%α −4.43% · $58.19
- T+6 · todayOpen
- T+20 · in 20d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
10x Genomics reported Q3 2026 revenue of $150.7M, slightly above the $147.8M consensus, with EPS of -$0.15 (GAAP) vs consensus of -$0.02 (adjusted basis mismatch). Gross margin improved to 75% from 67% a year ago, and the company raised its full-year 2026 revenue guidance to $625M-$635M from $610M-$630M. The commercial launch of Atera and introduction of Sentira platform are positive developments, but the EPS miss on the consensus basis tempers the outlook.
Key Financial Metrics
Key Facts
- Q3 2026 revenue $150.7M, up 1% YoY from $149.0M
- GAAP EPS -$0.15 vs consensus -$0.02 (basis mismatch: GAAP vs adjusted)
- Gross margin improved to 75% from 67% YoY
- Operating loss narrowed to $16.1M from $32.2M YoY
- Full-year 2026 revenue guidance raised to $625M-$635M from $610M-$630M
- Began commercial shipments of Atera platform
- Introduced Sentira cloud analysis platform with NVIDIA and Anthropic AI
- Cash and marketable securities $575.7M
Financial Impact
Revenue beat consensus by ~$2.9M (2.0%), guidance raised by $15M at midpoint
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Single Cell Consumables | $93.1M | +0.7% |
| Spatial Consumables | $41.2M | +16.4% |
| Single Cell Instruments | $3.8M | -23.2% |
| Spatial Instruments | $3.1M | -56.5% |
| Services | $9.0M | +11.0% |
| License and Royalty | $457.0K | -53.5% |
Risk Factors
- EPS consensus basis unclear: GAAP EPS -$0.15 vs consensus -$0.02 suggests a miss if consensus is on an adjusted basis, but no adjusted EPS figure was provided
- Revenue growth remains modest at 1% YoY, below the raised guidance implied growth of 4-6%
- Litigation expenses increased, partially offsetting cost reductions
- Document contains text addressed to automated readers (forward-looking statements boilerplate)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-prn-302931240 |
Track record
28 reports on TXG
1 of 6 bullish or bearish reports moved the stock their way by T+60. Best: +8.89% at T+60 after the Aug 19, 2026 report. 2 of 7 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $55.40 Now $54.99 −0.74% settles Feb 12
- Nov 6, 202610d ago 3 Neutral 1/10 Entry $65.05 Now $54.99 −15.47% settles Feb 5
- Nov 6, 202610d ago 3 Neutral 1/10 Entry $65.05 Now $54.99 −15.47% settles Feb 5
- Nov 5, 202611d ago 8-K Bullish 6/10 No price data
- Nov 5, 202611d ago Press Release Mixed 5/10 Viewing Entry $59.28 Now $54.99 −7.24% settles Feb 4
- Nov 2, 202614d ago 8-K Neutral 2/10 Entry $65.29 Now $54.99 −15.78% settles Feb 1
- Oct 23, 202624d ago Institutional Cluster Neutral 2/10 Entry $71.55 Now $54.99 −23.14% settles Jan 21
- Oct 7, 20265w ago SC 13G/A Neutral 2/10 Entry $77.28 Now $54.99 −28.84% settles Jan 5
- Sep 24, 20267w ago Insider Cluster Neutral 3/10 Entry $85.71 Now $54.99 −35.84% settles Dec 21
- Sep 22, 20267w ago 144 Neutral 2/10 Entry $75.62 Now $54.99 −27.28% settles Dec 17
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers